Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    44,339 result(s) found. Displaying page 409 of 2,217.
    «« First « Previous 405  406  407  408  409  410  411  412  413  Next» Last»»
    EudraCT Number: 2015-001708-69 Sponsor Protocol Number: 20184 Start Date*: 2015-07-15
    Sponsor Name:Merck KGaA
    Full Title: An Open Study of the Safety and Efficacy of Saizen®, (Recombinant Human Growth Hormone, r-hGH), in Children Born With Serious Intra-uterine Growth Retardation (IUGR) Treated to Final Height
    Medical condition: Children Born With Serious Intra-uterine Growth Retardation
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-001276-56 Sponsor Protocol Number: AIDA Start Date*: 2014-07-11
    Sponsor Name:North Bristol NHS - Southmead Hospital
    Full Title: A prospective, open label, randomised controlled clinical trial, with pharmacokinetic-pharmacodynamic validation, to compare antimicrobial treatment with oral minocycline plus rifampicin to treatme...
    Medical condition: Complicated Skin and Skin Structure infections caused by Methicillin Resistant Staphylococcus Aureus
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed) GR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-003000-39 Sponsor Protocol Number: 2018.0158 Start Date*: 2019-01-09
    Sponsor Name:St George’s University of London
    Full Title: A Multi-centre, Multiple-dose, Open-label Study to Investigate the Safety, Tolerability, Pharmacodynamics, and Efficacy of Erythrocyte Encapsulated Thymidine Phosphorylase (EE-TP) in Patients with ...
    Medical condition: Mitochondrial Neurogastrointestinal Encephalomyopathy (MNGIE)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10010331 - Congenital, familial and genetic disorders 10058799 Mitochondrial encephalomyopathy PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2019-003462-40 Sponsor Protocol Number: 18IC07 Start Date*: 2020-03-30
    Sponsor Name:Great Ormond Street Hospital for Children NHS Trust
    Full Title: Phase 1 , open label study of CRISPR-CAR genome edited T cells (TT52CAR19) in relapsed /refractory B Cell Acute Lymphoblastic Leukaemia
    Medical condition: Relapsed/ refractory B- cell acute lymphoid leukaemia
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2014-004560-38 Sponsor Protocol Number: M04-729 Start Date*: 2014-11-12
    Sponsor Name:Abbott Deutschland GmbH & Co. KG
    Full Title: A Multi-Center, Randomized, Double-blind, Placebo-controlled Study of Adalimumab for the Induction of Clinical Remission in Japanese Subjects With Crohn's Disease.
    Medical condition: Crohn's Disease
    Disease: Version SOC Term Classification Code Term Level
    17.1 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-003772-23 Sponsor Protocol Number: ZLB05_006CR Start Date*: 2015-04-14
    Sponsor Name:CSL Behring AG
    Full Title: A Multicenter Extension Study on the Safety and Efficacy of IgPro10 in Patients With Primary Immunodeficiency (PID)
    Medical condition: Primary Immune Deficiency (Common Variable Immunodeficiency and X-linked agammaglobulinemia)
    Disease: Version SOC Term Classification Code Term Level
    17.1 10010331 - Congenital, familial and genetic disorders 10064859 Primary immunodeficiency syndrome PT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-003701-15 Sponsor Protocol Number: 20101228 Start Date*: 2015-05-01
    Sponsor Name:Amgen Inc.
    Full Title: A Randomized, Double-blind, Placebo-controlled Study With an Open Label Extension to Evaluate the Safety and Efficacy of Brodalumab in Subjects With Axial Spondyloarthritis
    Medical condition: Axial Spondyloarthritis
    Disease: Version SOC Term Classification Code Term Level
    18.0 10028395 - Musculoskeletal and connective tissue disorders 10051265 Spondyloarthropathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-004172-32 Sponsor Protocol Number: A6281280 Start Date*: 2015-04-01
    Sponsor Name:Pfixer Inc
    Full Title: A Four-Year Open-Label Multi-Center Randomized Two-Arm Study of Genotropin in Idiopathic Short Stature Subjects: Comparing an Individualized, Target-Driven Treatment Regimen to Standard Dosing of G...
    Medical condition: Idiopathic short stature (ISS)
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2019-002366-12 Sponsor Protocol Number: Protocolversion1.0 Start Date*: 2020-04-08
    Sponsor Name:Johns Hopkins University
    Full Title: ADalimumab Vs. conventional ImmunoSupprEssion for uveitis (ADVISE)Trial
    Medical condition: Uveitic macular oedema
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004853 10022557 Intermediate uveitis LLT
    20.0 100000004853 10033687 Panuveitis LLT
    20.1 100000004862 10036370 Posterior uveitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2019-001023-13 Sponsor Protocol Number: Ox_Psych_PAXD Start Date*: 2019-11-11
    Sponsor Name:University of Oxford / Clinical Trials and Research Governance
    Full Title: PAX-D: Randomised placebo-controlled trial evaluating the efficacy and mechanism of pramipexole as add-on treatment for people with treatment resistant depression
    Medical condition: Treatment resistant depression
    Disease: Version SOC Term Classification Code Term Level
    21.1 10037175 - Psychiatric disorders 10057840 Major depression PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2018-002094-22 Sponsor Protocol Number: FiHM006 Start Date*: 2019-01-17
    Sponsor Name:Fundación de investigación de HM Hospitales
    Full Title: A Phase II Trial to Assess the Evolution of KRAS Mutation Load by Liquid Biopsy in Patients with Resectable Pancreatic Ductal Adenocarcinoma Treated with Neoadjuvant NALIRINOX
    Medical condition: Resectable Pancreatic Ductal Adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10033602 Pancreatic adenocarcinoma resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-000904-88 Sponsor Protocol Number: 1218.149 Start Date*: 2014-08-05
    Sponsor Name:Boehringer Ingelheim Ellas SA
    Full Title: A 24 week randomized, double-blind, placebo-controlled, parallel group, efficacy and safety trial of once daily linagliptin, 5 milligrams orally, as add on to basal insulin in elderly Type 2 Diabet...
    Medical condition: Type 2 Diabetes Mellitus
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: GR (Completed) ES (Completed) DK (Completed) GB (Completed) FI (Completed) DE (Completed) BE (Completed) IE (Completed)
    Trial results: View results
    EudraCT Number: 2014-002509-39 Sponsor Protocol Number: RD.03.SPR.102710 Start Date*: 2014-10-30
    Sponsor Name:GALDERMA R&D
    Full Title: Effect of Patient Education on Treatment Adherence and Satisfaction among Acne Patients Receiving Once-Daily EpiduoTM Gel Treatment in Primary Care Clinics
    Medical condition: Acne vulgaris
    Disease: Version SOC Term Classification Code Term Level
    17.0 10040785 - Skin and subcutaneous tissue disorders 10040785 Skin and subcutaneous tissue disorders SOC
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-003484-36 Sponsor Protocol Number: MP1032-CT04 Start Date*: 2018-01-19
    Sponsor Name:MetrioPharm AG
    Full Title: A Phase II, Multicenter, Double-blind, Placebo-controlled, Efficacy and Safety Study of Two Oral Doses (150 mg bid / 300 mg bid) of MP1032 in Male and Female Patients with Moderate-to-Severe Chroni...
    Medical condition: chronic Psoriasis Plaque moderate-to-severe
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2004-000512-17 Sponsor Protocol Number: 20040138 Start Date*: 2004-10-01
    Sponsor Name:Amgen Inc
    Full Title: A Randomized, Double-Blind, Placebo-controlled Study to Evaluate AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Androgen-Deprivation Therapy for Non-metastatic Prostate Cancer
    Medical condition: Bone loss in pateints undergoing androgen-deprivation therapy (ADT) for non-metastatic prostate cancer.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10049470 Bone density decreased LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FI (Completed) HU (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2004-000007-18 Sponsor Protocol Number: GlaxoSmithKline, SCO100470 Start Date*: 2004-06-30
    Sponsor Name:GlaxoSmithKline AB
    Full Title: A Multicentre, Randomised, Double-Blind, Parallel Group, 24 Week Study to Compare the Effect of the Salmeterol/Fluticasone Propionate Combination Product (SERETIDE) 50/250mcg with Salmeterol 50mcg ...
    Medical condition: Study is to be conducted in patients with COPD whose airflow limitation, in terms of percentage of predicted FEV1 is between 50-80% normal.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2010-021001-21 Sponsor Protocol Number: SMART-2010-1 Start Date*: 2010-09-27
    Sponsor Name:Allergie-Centrum-Charité
    Full Title: An exploratory, randomised, double-blind, placebo controlled crossover study to assess the efficacy of 20 mg Rupatadine on the treatment of mastocytosis symptoms
    Medical condition: Mastocytosis is characterized by an excessive increase in the number of mast cells in different tissues. Symptoms result either from organ infiltration or frequently from the release of proinflamma...
    Disease: Version SOC Term Classification Code Term Level
    12.1 10052577 Pure dermal mastocytosis LLT
    12.1 10056452 Indolent systemic mastocytosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2004-001388-23 Sponsor Protocol Number: PRO-RENAL-REG-062 Start Date*: 2004-11-09
    Sponsor Name:Baxter R&D Europe SCRL
    Full Title: A Study to Evaluate the Efficacy and Safety of Extraneal Physiological pH Compared with Current Extraneal in Patients Receiving Continuous Ambulatory Peritoneal Dialysis (CAPD).
    Medical condition: End Stage Renal Disease patients receiving continuous ambulatiry peritoneal dialysis (CAPD)
    Disease: Version SOC Term Classification Code Term Level
    6.1 10014646 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) GB (Completed) DK (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2004-001397-92 Sponsor Protocol Number: CSTI571 0110 Extension2 Start Date*: Information not available in EudraCT
    Sponsor Name:Novartis Pharmaceuticals UK Ltd
    Full Title: An extension to a phase II study to determine the efficacy and safety of STI571 in patients with chronic myeloid leukemia who are refractory to or intolerant of interferon-alpha
    Medical condition: Philadelphia chromosome-opositive chronic myeloid leukamia in myeloid blast crisis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2004-002317-37 Sponsor Protocol Number: HMR4003B/4034 Start Date*: 2004-11-18
    Sponsor Name:Aventis Inc.
    Full Title: OPEN-LABEL STUDY TO DETERMINE HOW PRIOR THERAPY WITH ALENDRONATE OR RISEDRONATE IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS INFLUENCES THE CLINICAL EFFECTIVENESS OF TERIPARATIDE
    Medical condition: Post-menopausal woman with 1 or more prevalent osteoporotic fractures and a BMD (spine or hip) of < -2.5 (see protocol amendment 2).
    Disease: Version SOC Term Classification Code Term Level
    7.0 10031285 LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 405  406  407  408  409  410  411  412  413  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Jun 01 11:46:02 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA